Abstract:Activation of the toll-like receptors 7 and 8 has emerged as a promising strategy for cancer immunotherapy. Herein, we report the design and synthesis of a series of pyrido[3,2-d]pyrimidine-based toll-like receptor 7/8 dual agonists that exhibited potent and near-equivalent agonistic activities toward TLR7 and TLR8. In vitro, compounds 24e and 25a significantly induced the secretion of IFN-α, IFN-γ, TNF-α, IL-1β, IL-12p40, and IP-10 in human peripheral blood mononuclear cell assays. In vivo, compounds 24e, 24m, and 25a significantly suppressed tumor growth in CT26 tumor-bearing mice by remodeling the tumor microenvironment. Additionally, compounds 24e, 24m, and 25a markedly improved the antitumor activity of PD-1/PD-L1 blockade. In particular, compound 24e combined with the anti-PD-L1 antibody led to complete tumor regression. These results demonstrated that TLR7/8 agonists (24e, 24m, and 25a) held great potential as single agents or in combination with PD-1/PD-L1 blockade for cancer immunotherapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00179?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00179</a>.Homology and similarity analysis between TLR7 and 8; agonistic activities of compounds 24e, 25a, and 26a in other homologous TLRs; supplementary multiplexed immunoassays for cytokines; synergy analysis of tumor size and the survival rate; representative flow cytometric analysis of tumor-infiltrating immune cells; detection of absolute counts of tumor-infiltrating immune cells and synergy analysis; relationships between the TVs and the amounts of immune cells; phospholipidosis detection of 24e, 24m, and 25a; synthesis of compounds 16a, 27, and 35; NMR spectra of target compounds; and HPLC traces of compounds 5, 24e, 24k, 24m, 25a, and 34 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_002.csv">CSV</a>)Molecular docking for GS-9620 into TLR7 and molecular docking for 17d, 24e, 24m, and 34, into TLR7 and TLR8 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_003.zip">ZIP</a>)This article has not yet been cited by other publications.

Design and Synthesis of 3-(2 H -Chromen-3-yl)-5-aryl-1,2,4-oxadiazole Derivatives as Novel Toll-like Receptor 2/1 Agonists That Inhibit Lung Cancer In Vitro and In Vivo

The Development of a Highly Potent and Selective Human Toll-like Receptor 2 Agonist: Synthesis and Biological Evaluation of CaLGL-1 and Its Derivatives

Design, Synthesis, and Structure–Activity Relationship of N -Aryl- N ′-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy

Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy

Design and Optimisation of a Small-Molecule TLR2/4 Antagonist for Anti-Tumour Therapy.

TLR1/2 Specific Small‐Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes

Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma

Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.

Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics

Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8h)-one Derivatives As Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.

Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

Identification and immunological evaluation of novel TLR2 agonists through structural optimization of Diprovocim

Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors 7 and 8.

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

Novel 1,3,4-Oxadiazole Thioether Derivatives Targeting Thymidylate Synthase As Dual Anticancer/antimicrobial Agents.

A Chemically Defined TLR3 Agonist with Anticancer Activity

Synthesis, evaluation and molecular dynamics study of human toll-like receptor 2/6 specific monoacyl lipopeptides as candidate immunostimulants

Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy

A Conjugate of Octamer-Binding Transcription Factor 4 and Toll-Like Receptor 7 Agonist Prevents the Growth and Metastasis of Testis Embryonic Carcinoma.